['diabetes mellitus, type 1']
['canagliflozin 100 mg', 'canagliflozin 300 mg', 'placebo']

        Inclusion Criteria:

          -  Must have type 1 diabetes mellitus (T1DM) for at least 1 year

          -  Must have have inadequate glycemic control (as defined by glycosylated hemoglobin
             level of >= 7.0% to <= 9.0%) on basal plus bolus insulin at screening

          -  Must have body mass index 21 to 35 kg/m2 inclusive

          -  Must be on a total daily dose of insulin >= 0.6 IU/kg at screening

          -  Must be on a stable insulin regimen for at least 8 weeks prior to screening

        Exclusion Criteria:

          -  History of T2DM, pancreas or β-cell transplantation, or diabetes secondary to
             pancreatitis or pancreatectomy

          -  Severe hypoglycemia (defined as an event required assistance from another person, or
             which resulted in seizure or loss of consciousness) within 6 months prior to study
             start

          -  Diabetic ketoacidosis within 6 months prior to study start

          -  History of hereditary glucose-galactose malabsorption or primary renal glycosuria

          -  An ongoing, inadequately controlled thyroid disorder
      